Perjeta® (pertuzumab) – Expanded indication
December 20, 2017 – Genentech announced the FDA approval of Perjeta (pertuzumab) for use in combination with Herceptin® (trastuzumab) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.
Top